Abstract
Purpose
To investigate the mechanism of cell death induced by the N-alkylated prodigiosin analogue, 2,2′-[3-methoxy-1′amyl-5′-methyl-4-(1′′-pyrryl)] dipyrryl-methene (MAMPDM) in S-180 and EL-4 tumour cell lines.
Methods
Effect of MAMPDM on cell viability was assessed by MTT dye conversion. Induction of apoptosis was assessed by monitoring caspase 3 activity using a fluorogenic substrate, fragmentation of DNA by gel electrophoresis and sub-diploid DNA containing cells by flowcytometry. Necrosis was estimated by flowcytometric analysis of the uptake of propidium iodide.
Results
MAMPDM inhibited the proliferation of murine fibrosarcoma, S-180 cells and induced cell death. Investigations into the mechanism of cell death by MAMPDM in S-180 cells showed absence of hallmarks of apoptotic cell death such as activation of caspase 3, DNA fragmentation and presence of cells with sub-diploid DNA content. However, there was a rapid loss of membrane integrity as assessed by uptake of propidium iodide, which is characteristic of necrosis. In contrast to induction of necrosis in S-180 cells, MAMPDM induced apoptotic cell death in EL-4 cells as evident by activation of caspase 3, fragmentation of DNA and sub-diploid DNA containing cells.
Conclusions
MAMPDM could induce cell death by either apoptosis or necrosis depending upon the cell type. This would be of advantage in elimination of tumor cells defective in apoptotic pathway and therefore, refractory to the conventional therapies.
Similar content being viewed by others
References
Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 20:239–257
Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12:382–393
Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798–4811
Papadopoulos K (2006) Targeting the Bcl-2 family in cancer therapy. Semin Oncol 33:449–456
Yamamoto C, Takemoto H, Kuno K, Yamamoto D, Tsubura A, Kamata K, Hirata H, Yamamoto A, Kano H, Seki T, Inoue K (1999) Cycloprodigiosin hydrochloride, a new H+/Cl− symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 30:894–902
Montaner B, Navarro S, Pique M, Vilaseca M, Martinell M, Giralt E, Gil J, Perez-Tomas R (2000) Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 131:585–593
Liu R, Cui CB, Duan L, Gu QQ, Zhu WM (2005) Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomycete Saccharopolyspora sp. nov. Arch Pharm Res 28:1341–1344
Nakashima T, Tamura T, Kurachi M, Yamaguchi K, Oda T (2005) Apoptosis-mediated cytotoxicity of prodigiosin-like red pigment produced by gamma-Proteobacterium and its multiple bioactivities. Biol Pharm Bull 28:2289–2295
Campàs C, Dalmau M, Montaner B, Barragan M, Bellosillo B, Colomer D, Pons G, Perez-Tomas R, Gil J (2003) Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukaemia. Leukemia 17:746–750
Castillo-Avila W, Abal M, Robine S, Perez-Tomas R (2005) Non-apoptotic concentrations of prodigiosin (H+/Cl− symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 78:121–127
Pérez-Tomás R, Montaner B, Llagostera E, Soto-Cerrato V (2003) The prodigiosins, proapoptotic drugs with anticancer properties. Biochem Pharmacol 66:1447–1452
Zhang J, Shen Y, Liu J, Wei D (2005) Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 69:407–414
Variyar PS, Chander R, Venkatachalam SR, Bongirwar DR (2002) A new red pigment from an alkalophilic Micrococcus species. Ind J Chem 14B:232–233
Pandey R, Chander R, Sainis KB (2003) A novel prodigiosin-like immunosuppressant from an alkalophilic Micrococcus sp. Int Immunopharmacol 3:159–167
Deorukhkar AA, Chander R, Ghosh SB, Sainis KB (2007) A Serratia marcescens strain producing a novel N-alkylated prodigiosin analogue. Res Microbiol (in press)
Alfaro G, Lomeli C, Ocadiz R, Ortega V, Barrera R, Ramirez M, Nava G (1992) Immunologic and genetic characterization of S-180, a cell line of murine origin capable of growing in different inbred strains of mice. Vet Immunol Immunopathol 30:385–398
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining. J Immunol Methods 139:271–279
Troyano A, Fernández C, Sancho P, de Blas E, Aller P (2001) Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. J Biol Chem 276:47107–47115
Hannun YA (1997) Apoptosis and dilemma of cancer chemotherapy. Blood 89:1845–1853
Kauffmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42–49
Leist M, Jäättelä M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2:589–598
Okada M, Adachi S, Imai T, Watanabe K, Toyokuni S, Ueno M, Zervos AS, Kroemer G, Nakahata T (2004) A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 103:2299–2307
Manderville RA (2001) Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products. Curr Med Chem Anticancer Agents 1:195–218
Laster SM, Wood JG, Gooding LR (1988) Tumour necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 141:2629–2635
Jänicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357–9360
Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R (2004) Mitochondria mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 68:1345–1352
Kitanaka C, Kuchino Y (1999) Caspase-independent programmed cell death with necrotic morphology. Cell Death Diff 6:508–515
Jiang MC, Yang-Yen HF, Yen JJ, Lin JK (1996) Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 26:111–120
Wang W, Guo OL, You OD, Zhang K, Yang Y, Yu J, Liu W, Zhao L, Gu HY, Hu Y, Tan Z, Wang XT (2006) The anticancer activities of wogonin in murine sarcoma S-180 both in vitro and in vivo. Biol Pharm Bull 29:1132–1137
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Sem Cancer Biol 14:433–439
Hirt UA, Gantner F, Leist M (2000) Phagocytosis of nonapoptotic cells dying by caspase-independent mechanisms. J Immunol 164:6520–6529
Reiter I, Krammer B, Schwamberger G (1999) Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol 163:1730–1732
Bursch W (2001) The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Diff 8:569–581
Proskuryakov SY, Konoplyannikov AG, Gabai VL (2003) Necrosis: a specific form of programmed cell death? Exp Cell Res 283:1–16
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deorukhkar, A.A., Chander, R., Pandey, R. et al. A novel N-alkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type. Cancer Chemother Pharmacol 61, 355–363 (2008). https://doi.org/10.1007/s00280-007-0475-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0475-y